


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**

**EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Company, has entered into an exclusive license agreement (the “**Agreement**”) with a fully owned subsidiary of Sanofi S.A. (“**Sanofi**”), for the global development, manufacturing and commercialization of the Group’s JAK/ROCK inhibitor, rovadicitinib.

Subject to the terms and conditions of the Agreement, the Group shall grant Sanofi an exclusive global license to develop, manufacture and commercialize rovadicitinib. The Group is eligible to receive an upfront payment of US\$135 million plus potential development, regulatory and sales milestone payments of up to US\$1,395 million, as well as up to double-digit tiered royalties based on the annual net sales of rovadicitinib. The effectiveness of the agreement is subject to customary closing conditions, including regulatory clearances.

**ABOUT ROVADICITINIB**

Rovadicitnib is a global first-in-class, novel, potent oral small-molecule JAK/ROCK inhibitor. As a dual-target inhibitor, rovadicitnib exerts synergistic anti-inflammatory and anti-fibrotic effects through a dual mechanism of action. It targets the JAK/STAT pathway to directly suppress inflammatory signaling, curtailing the production of inflammatory cytokines by myeloid cells. Concurrently, it inhibits the ROCK pathway, which modulates STAT3/STAT5 phosphorylation to downregulate overactivated T helper cells (Th17) and enhance the function of regulatory T cells (Treg), thereby restoring immune homeostasis.

In February 2026, rovadicitnib (Brand name: Anxu (安煦®)) was approved for marketing by China's National Medical Products Administration (NMPA) for the first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF).

Rovadicitnib has also demonstrated breakthrough potential in the treatment of chronic graft-versus-host disease (cGVHD): in China, it has advanced to the Phase III clinical trial stage and was granted Breakthrough Therapy Designation (BTD) by the CDE in August 2025; in the United States, it has been approved to conduct Phase II clinical studies. The Phase Ib/IIa clinical data for cGVHD, published in *Blood*, demonstrated superior 12-month failure-free survival (FFS) and enhanced responses in fibrosis-dominated organs compared to other approved therapies, as well as the potential to overcome ruxolitinib resistance.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 4 March 2026

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*